Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target

  • Kang, Ben (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Choe, Yon Ho (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2017.12.18
  • Accepted : 2018.01.02
  • Published : 2018.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

The emergence of mucosal healing as a treatment goal that could modify the natural course of Crohn's disease and the accumulating evidence showing that biologics are most effective in achieving mucosal healing, along with the success of early treatment regimens for rheumatoid arthritis, have led to the identification of early Crohn's disease and development of the concept of catching the therapeutic window during the early disease course. Thus, an increasing number of pediatric gastroenterologists are adopting an early biologic treatment strategy with or without an immunomodulator. Although early biologic treatment is effective, cost and overtreatment are issues that limit its early use. Currently, there are insufficient data on who will benefit most from early biologics, as well as on who will not need early or even any biologics. For now, top-down biologics should be considered for patients with currently known high-risk factors of poor outcomes. For other patients, close, objective monitoring and accelerating the step-up process by means of a treat-to-target approach seems the best way to catch the therapeutic window in early pediatric Crohn's disease. The individual benefits of immunomodulator addition during early biologic treatment should be weighed against its risks and decision on early combination treatment should be made after comprehensive discussion with each patient and guardian.

Keywords

References

  1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57. https://doi.org/10.1016/S0140-6736(07)60751-X
  2. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50. https://doi.org/10.1097/00054725-200207000-00002
  3. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010;139: 1147-55. https://doi.org/10.1053/j.gastro.2010.06.070
  4. Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr 2015;169:1053-60. https://doi.org/10.1001/jamapediatrics.2015.1982
  5. Kim S. Surgery in pediatric crohn's disease: indications, timing and post-operative management. Pediatr Gastroenterol Hepatol Nutr 2017;20:14-21. https://doi.org/10.5223/pghn.2017.20.1.14
  6. Walters TD, Griffiths AM. Mechanisms of growth impairment in pediatric Crohn's disease. Nat Rev Gastroenterol Hepatol 2009;6:513-23. https://doi.org/10.1038/nrgastro.2009.124
  7. Walters TD, Hyams JS. Can early anti-TNF-${\alpha}$ treatment be an effective therapeutic strategy in children with Crohn's disease? Immunotherapy 2014;6:799-802. https://doi.org/10.2217/imt.14.57
  8. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. https://doi.org/10.1016/S0140-6736(02)08512-4
  9. Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-20. https://doi.org/10.1016/S1542-3565(04)00414-8
  10. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132:863-73. https://doi.org/10.1053/j.gastro.2006.12.003
  11. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65. https://doi.org/10.1053/j.gastro.2006.11.041
  12. Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012;143:365-74.e2. https://doi.org/10.1053/j.gastro.2012.04.046
  13. Ordas I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut 2011;60:1754-63. https://doi.org/10.1136/gutjnl-2011-300934
  14. Antunes O, Filippi J, Hebuterne X, Peyrin-Biroulet L. Treatment algorithms in Crohn's - up, down or something else? Best Pract Res Clin Gastroenterol 2014; 28:473-83. https://doi.org/10.1016/j.bpg.2014.05.001
  15. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619-35. https://doi.org/10.1136/gutjnl-2012-302830
  16. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13. https://doi.org/10.1053/j.gastro.2003.11.014
  17. Froslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22. https://doi.org/10.1053/j.gastro.2007.05.051
  18. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138: 463-8. https://doi.org/10.1053/j.gastro.2009.09.056
  19. De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis 2013;19:429-44. https://doi.org/10.1002/ibd.22977
  20. Frolkis AD, Dykeman J, Negron ME, Debruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013;145:996-1006. https://doi.org/10.1053/j.gastro.2013.07.041
  21. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7. https://doi.org/10.1136/ard.2009.123919
  22. Allen PB, Gower-Rousseau C, Danese S, Peyrin-Biroulet L. Preventing disability in inflammatory bowel disease. Therap Adv Gastroenterol 2017;10:865-76. https://doi.org/10.1177/1756283X17732720
  23. Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panes J, et al. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol 2012;107: 1770-6. https://doi.org/10.1038/ajg.2012.117
  24. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011;17:1415-22. https://doi.org/10.1002/ibd.21506
  25. Danese S, Fiorino G, Fernandes C, Peyrin-Biroulet L. Catching the therapeutic window of opportunity in early Crohn's disease. Curr Drug Targets 2014;15:1056-63. https://doi.org/10.2174/1389450115666140908125738
  26. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7. https://doi.org/10.1016/S0140-6736(08)60304-9
  27. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95. https://doi.org/10.1056/NEJMoa0904492
  28. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 2015;386:1825-34. https://doi.org/10.1016/S0140-6736(15)00068-9
  29. Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease-a SONIC post hoc analysis. Aliment Pharmacol Ther 2015;41:734-46. https://doi.org/10.1111/apt.13139
  30. Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014;12:414-22.e5. https://doi.org/10.1016/j.cgh.2013.06.019
  31. Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-${\alpha}$ vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014;146:383-91. https://doi.org/10.1053/j.gastro.2013.10.027
  32. Kang B, Choi SY, Kim HS, Kim K, Lee YM, Choe YH. Mucosal healing in paediatric patients with moderate- to-severe luminal crohn's disease under combined immunosuppression: escalation versus early treatment. J Crohns Colitis 2016;10:1279-86. https://doi.org/10.1093/ecco-jcc/jjw086
  33. Kierkus J, Dadalski M, Szymanska E, Oracz G, Wegner A, Gorczewska M, et al. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderateto-severe Crohn's disease. Eur J Gastroenterol Hepatol 2012;24:495-500. https://doi.org/10.1097/MEG.0b013e32835159f2
  34. Nobile S, Gionchetti P, Rizzello F, Calabrese C, Campieri M. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center. Eur J Gastroenterol Hepatol 2014;26: 458-65. https://doi.org/10.1097/MEG.0000000000000045
  35. Nuti F, Civitelli F, Bloise S, Oliva S, Aloi M, Latorre G, et al. Prospective evaluation of the achievement of mucosal healing with anti-TNF-${\alpha}$ therapy in a paediatric Crohn's disease cohort. J Crohns Colitis 2016;10:5-12. https://doi.org/10.1093/ecco-jcc/jjv126
  36. Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997;113:118-26. https://doi.org/10.1016/S0016-5085(97)70116-1
  37. Kugathasan S, Saubermann LJ, Smith L, Kou D, Itoh J, Binion DG, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007;56:1696-705. https://doi.org/10.1136/gut.2006.116467
  38. Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004;36:342-7. https://doi.org/10.1016/j.dld.2003.12.014
  39. Crombe V, Salleron J, Savoye G, Dupas JL, Vernier-Massouille G, Lerebours E, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis 2011;17:2144-52. https://doi.org/10.1002/ibd.21615
  40. Church PC, Guan J, Walters TD, Frost K, Assa A, Muise AM, et al. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. Inflamm Bowel Dis 2014;20:1177-86. https://doi.org/10.1097/MIB.0000000000000083
  41. Choi J, Kang B, Kim MJ, Sohn I, Lee HJ, Choe YH. Early infliximab yields superior long-term effects on linear growth in pediatric Crohn's disease patients. Gut Liver 2018. doi: 10.5009/gnl17290. [Epub ahead of print]
  42. Lee YM, Kang B, Lee Y, Kim MJ, Choe YH. Infliximab "Top-Down" strategy is superior to "Step-Up" in maintaining long-term remission in the treatment of pediatric crohn disease. J Pediatr Gastroenterol Nutr 2015; 60:737-43. https://doi.org/10.1097/MPG.0000000000000711
  43. Wauters L, Smets F, De Greef E, Bontems P, Hoffman I, Hauser B, et al. Long-term outcomes with anti-TNF therapy and accelerated step-up in the prospective pediatric belgian crohn's disease registry (BELCRO). Inflamm Bowel Dis 2017;23:1584-91. https://doi.org/10.1097/MIB.0000000000001193
  44. Kugathasan S, Denson LA, Walters TD, Kim MO, Marigorta UM, Schirmer M, et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet 2017;389:1710-8. https://doi.org/10.1016/S0140-6736(17)30317-3
  45. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41.e1. https://doi.org/10.1016/j.cgh.2010.09.016
  46. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8:1179-207. https://doi.org/10.1016/j.crohns.2014.04.005
  47. Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a quebec claims database study. Inflamm Bowel Dis 2015;21:1847-53. https://doi.org/10.1097/MIB.0000000000000457
  48. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5. https://doi.org/10.1136/gut.2004.049460
  49. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a metaanalysis. Clin Gastroenterol Hepatol 2009;7:874-81. https://doi.org/10.1016/j.cgh.2009.01.004
  50. Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 2014;12:1443-51. https://doi.org/10.1016/j.cgh.2014.01.021
  51. Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology 2017;152:1901-14.e3. https://doi.org/10.1053/j.gastro.2017.02.004
  52. Cozijnsen MA, Escher JC, Griffiths A, Turner D, de Ridder L. Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2015;21:951-61. https://doi.org/10.1097/MIB.0000000000000245
  53. Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014;146:681-8.e1. https://doi.org/10.1053/j.gastro.2013.11.024
  54. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36. https://doi.org/10.1053/j.gastro.2008.01.012
  55. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009;104:2524-33. https://doi.org/10.1038/ajg.2009.322
  56. Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The role of combination therapy in pediatric inflammatory bowel disease (IBD): a clinical report from the North American Society for pediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr 2017. doi: 10.1097/MPG.0000000000001850. [Epub ahead of print]
  57. Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol 2015;13: 1042-50.e2. https://doi.org/10.1016/j.cgh.2013.09.006
  58. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010;4:63-101. https://doi.org/10.1016/j.crohns.2009.09.009
  59. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6. https://doi.org/10.1053/j.gastro.2005.12.019
  60. Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003;52:552-7. https://doi.org/10.1136/gut.52.4.552
  61. Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink-van de Kruijs MA, Cilissen M, Engels LG, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009;104:371-83. https://doi.org/10.1038/ajg.2008.38
  62. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002;97: 947-53.
  63. Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 2013;10:345-51. https://doi.org/10.1038/nrgastro.2013.31
  64. Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008;6:1105-11. https://doi.org/10.1016/j.cgh.2008.04.032
  65. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002;123:679-88. https://doi.org/10.1053/gast.2002.35393
  66. Cleynen I, Gonzalez JR, Figueroa C, Franke A, McGovern D, Bortlik M, et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. Gut 2013;62:1556-65. https://doi.org/10.1136/gutjnl-2011-300777
  67. Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, et al. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis 2011;17:30-8. https://doi.org/10.1002/ibd.21386
  68. Dubinsky M. Have we changed the natural history of pediatric Crohn's disease with biologics? Dig Dis 2014;32:360-3. https://doi.org/10.1159/000358137
  69. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015;110:1324-38. https://doi.org/10.1038/ajg.2015.233
  70. Zubin G, Peter L. Predicting endoscopic crohn's disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis 2015;21:1386-91.

Cited by

  1. Mucosal Immunity Related to FOXP3 + Regulatory T Cells, Th17 Cells and Cytokines in Pediatric Inflammatory Bowel Disease vol.33, pp.52, 2018, https://doi.org/10.3346/jkms.2018.33.e336
  2. Characteristics and Incidence Trends for Pediatric Inflammatory Bowel Disease in Daegu-Kyungpook Province in Korea: a Multi-Center Study vol.33, pp.18, 2018, https://doi.org/10.3346/jkms.2018.33.e132
  3. Clinical Aspects and Treatments for Pediatric Inflammatory Bowel Diseases vol.22, pp.1, 2018, https://doi.org/10.5223/pghn.2019.22.1.50
  4. Therapeutic Efficacy of Exclusive Enteral Nutrition with Specific Polymeric Diet in Pediatric Crohn's Disease vol.22, pp.1, 2018, https://doi.org/10.5223/pghn.2019.22.1.72
  5. Meckel's Diverticulum Diagnosed in a Child with Suspected Small Bowel Crohn's Disease vol.22, pp.1, 2018, https://doi.org/10.5223/pghn.2019.22.1.98
  6. Acute pancreatitis associated with indigo naturalis in pediatric severe Crohn’s disease vol.17, pp.1, 2019, https://doi.org/10.5217/ir.2018.00104
  7. Clinical aspects and treatments for pediatric inflammatory bowel diseases vol.17, pp.1, 2018, https://doi.org/10.5217/ir.2018.00139
  8. Korean Children and Adolescents with Crohn's Disease Are More Likely to Present with Perianal Fistulizing Disease at Diagnosis Compared to Their European Counterparts vol.23, pp.1, 2018, https://doi.org/10.5223/pghn.2020.23.1.49
  9. Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients vol.35, pp.17, 2018, https://doi.org/10.3346/jkms.2020.35.e114
  10. Precision medicine for pediatric inflammatory bowel disease: a perspective vol.4, pp.2, 2020, https://doi.org/10.23838/pfm.2020.00058
  11. Anti-Mycobacterial Antibiotic Therapy Induces Remission in Active Paediatric Crohn’s Disease vol.8, pp.8, 2018, https://doi.org/10.3390/microorganisms8081112
  12. Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review vol.37, pp.9, 2018, https://doi.org/10.1007/s12325-020-01437-4
  13. Pearls and Pitfalls in MR Enterography Interpretation for Pediatric Patients vol.41, pp.5, 2020, https://doi.org/10.1053/j.sult.2020.05.011
  14. Prevention of thiopurine-induced early leukopenia in a Korean pediatric patient with Crohn's disease who turned out to possess homozygous mutations in NUDT15 R139C vol.37, pp.4, 2020, https://doi.org/10.12701/yujm.2020.00178
  15. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease vol.15, pp.4, 2018, https://doi.org/10.5009/gnl20134
  16. Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab vol.38, pp.3, 2018, https://doi.org/10.12701/yujm.2020.00878
  17. A child presents with perianal symptoms - how often is this Crohn's disease? vol.56, pp.9, 2018, https://doi.org/10.1016/j.jpedsurg.2020.11.016
  18. Incidentally Detected Asymptomatic Perianal Abscess in an Adolescent during Crohn's Disease Diagnosis: Is Routine Pelvic Imaging Required in Korean Pediatric Patients at Diagnosis? vol.24, pp.6, 2018, https://doi.org/10.5223/pghn.2021.24.6.564
  19. A qualitative study to explore symptoms and impacts of pediatric and adolescent Crohn’s disease from patient and caregiver perspective vol.5, pp.1, 2018, https://doi.org/10.1186/s41687-021-00321-1